文献速递乳腺癌

奥拉帕利单药作为未经治疗三阴性乳腺癌的原发治疗

Olaparib monotherapy as primary treatment in unselected triple negative breast cancer.
PubMed 文献 · Ann Oncol · 2020-11-24

PETREMAC II期试验评估奥拉帕利单药术前治疗32例原发TNBC,客观缓解率56.3%。同源重组缺陷(HR突变和/或BRCA1高甲基化)与缓解显著相关,低RAD51评分、高TIL或高PD-L1也与缓解相关。结论提示奥拉帕利在未经治疗且存在HR缺陷的TNBC中疗效高,不限于胚系HR突变。

要点

  • 奥拉帕利术前单药治疗原发TNBC的客观缓解率为56.3%。
  • HR突变和/或BRCA1高甲基化与奥拉帕利缓解显著相关。
  • 低RAD51评分、高TIL或高PD-L1表达与奥拉帕利缓解相关。

核心结论

  • 奥拉帕利在未经化疗且存在HR缺陷的原发TNBC中产生高临床缓解率,获益不限于胚系HR突变。

研究设计与样本

  • II期PETREMAC单臂试验,纳入原发TNBC>2 cm患者,奥拉帕利术前治疗最长10周后化疗。
  • 治疗前后肿瘤活检行360基因靶向DNA测序和BRCA1甲基化分析。
  • 治疗前样本行BRCAness、PAM50基因表达、RAD51 foci、TIL及PD-L1分析。

主要发现

  • 32例可评估患者中18例获客观缓解,OR为56.3%。
  • 缓解者中10/18携带HR突变(OR 55.6%,95%CI 33.7-75.4),非缓解者中1/14(OR 7.1%,95%CI 1.3-31.5,P=0.008)。
  • 无HR突变肿瘤中,缓解者6/8 vs 非缓解者3/13存在BRCA1高甲基化(P=0.03)。
  • 16/18缓解者(88.9%,95%CI 67.2-96.9)vs 4/14非缓解者(28.6%,95%CI 11.7-54.7,P=0.0008)携带HR突变和/或BRCA1甲基化。
  • 低RAD51评分、高TIL或高PD-L1表达均与奥拉帕利缓解相关。

关键数值与推荐

  • 客观缓解定义为奥拉帕利治疗后的OR,18/32例(56.3%)。
  • HR突变和/或BRCA1甲基化在缓解者中占88.9%(95%CI 67.2-96.9),非缓解者中占28.6%(95%CI 11.7-54.7,P=0.0008)。
  • 排除1例gPALB2和4例gBRCA1/2突变携带者后,12/14缓解者(85.7%,95%CI 60.1-96.0)vs 3/13非缓解者(23.1%,95%CI 8.2-50.3,P=0.002)携带体细胞HR突变和/或BRCA1甲基化。

临床怎么用

  • 对未经治疗的原发TNBC,可考虑以HR缺陷(HR突变和/或BRCA1高甲基化)及低RAD51、高TIL或高PD-L1筛选奥拉帕利术前治疗获益人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The antitumor efficacy of PARP inhibitors (PARPi) for breast cancer patients harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi monotherapy was ineffective in patients with metastatic triple negative breast cancer (TNBC) wild type for BRCA1/2, we hypothesized that PARPi may be effective in primary TNBCs without previous chemotherapy exposure. PATIENTS AND METHODS: In the phase II PETREMAC trial, patients with primary TNBC >2 cm received olaparib for up to 10 weeks before chemotherapy. Tumor biopsies collected before and after olaparib underwent targeted DNA sequencing (360 genes) and BRCA1 methylation analyses. In addition, BRCAness (multiplex ligation-dependent probe amplification), PAM50 gene expression, RAD51 foci, tumor-infiltrating lymphocytes (TILs) and PD-L1 analyses were performed on pretreatment samples. RESULTS: The median pretreatment tumor diameter was 60 mm (range 25-112 mm). Eighteen out of 32 patients obtained an objective response (OR) to olaparib (56.3%). Somatic or germline mutations affecting homologous recombination (HR) were observed in 10/18 responders [OR 55.6%, 95% confidence interval (CI) 33.7-75.4] contrasting 1/14 non-responders (OR 7.1%; CI 1.3-31.5, P = 0.008). Among tumors without HR mutations, 6/8 responders versus 3/13 non-responders revealed BRCA1 hypermethylation (P = 0.03). Thus, 16/18 responders (88.9%, CI 67.2-96.9), in contrast to 4/14 non-responders (28.6%, CI 11.7-54.7, P = 0.0008), carried HR mutations and/or BRCA1 methylation. Excluding one gPALB2 and four gBRCA1/2 mutation carriers, 12/14 responders (85.7%, CI 60.1-96.0) versus 3/13 non-responders (23.1%, CI 8.2-50.3, P = 0.002) carried somatic HR mutations and/or BRCA1 methylation. In contrast to BRCAness signature or basal-like subtype, low RAD51 scores, high TIL or high PD-L1 expression all correlated to olaparib response. CONCLUSION: Olaparib yielded a high clinical response rate in treatment-naïve TNBCs revealing HR deficiency, beyond germline HR mutations. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02624973.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Eikesdal HP, Yndestad S, Elzawahry A, et al. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Ann Oncol. 2020. PMID: 33242536. doi:10.1016/j.annonc.2020.11.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。